FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205583718> ?p ?o ?g. }

• W4205583718 endingPage "175883592110687" @default.
• W4205583718 startingPage "175883592110687" @default.
• W4205583718 abstract "Predictive markers for treatment response and survival outcome have not been identified in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemoimmunotherapy. We aimed to evaluate whether imaging biomarkers of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) and routinely assessed clinico-laboratory values were associated with clinical outcomes in patients with advanced NSCLC receiving pembrolizumab plus platinum-doublet chemotherapy as a first-line treatment.We retrospectively enrolled 52 patients with advanced NSCLC who underwent baseline 18F-FDG PET/CT before treatment initiation. PET/CT parameters and clinico-laboratory variables, constituting the prognostic immunotherapy scoring system, were collected. Optimal cut-off values for PET/CT parameters were determined using the maximized log-rank test for progression-free survival (PFS). A multivariate prediction model was developed based on Cox models for PFS, and a scoring system was established based on hazard ratios of the predictive factors.During the median follow-up period of 16.7 months (95% confidence interval: 15.7-17.7 months), 43 (82.7%) and 31 (59.6%) patients experienced disease progression and death, respectively. Objective response was observed in 23 (44.2%) patients. In the multivariate analysis, maximum standardized uptake value, metabolic tumour volume2.5, total lesion glycolysis2.5, and bone marrow-to-liver uptake ratio from the PET/CT variables and neutrophil-to-lymphocyte ratio (NLR) from the clinico-laboratory variables were independently associated with PFS. The scoring system based on these independent predictive variables significantly predicted the treatment response, PFS, and overall survival.PET/CT variables and NLR were useful biomarkers for predicting outcomes of patients with NSCLC receiving pembrolizumab and chemotherapy as a first-line treatment, suggesting their potential as effective markers for combined PD-1 blockade and chemotherapy." @default.
• W4205583718 created "2022-01-26" @default.
• W4205583718 creator A5000828978 @default.
• W4205583718 creator A5011980528 @default.
• W4205583718 creator A5017519850 @default.
• W4205583718 creator A5020903295 @default.
• W4205583718 creator A5031320827 @default.
• W4205583718 creator A5036720036 @default.
• W4205583718 creator A5048833234 @default.
• W4205583718 creator A5049113012 @default.
• W4205583718 creator A5057474625 @default.
• W4205583718 creator A5064697305 @default.
• W4205583718 creator A5071926090 @default.
• W4205583718 creator A5084782886 @default.
• W4205583718 date "2022-01-01" @default.
• W4205583718 modified "2023-09-25" @default.
• W4205583718 title "Predicting treatment outcomes using ¹⁸F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy" @default.
• W4205583718 cites W1982488143 @default.
• W4205583718 cites W2019607817 @default.
• W4205583718 cites W2021302897 @default.
• W4205583718 cites W2049553585 @default.
• W4205583718 cites W2052228957 @default.
• W4205583718 cites W2080682920 @default.
• W4205583718 cites W2088783247 @default.
• W4205583718 cites W2102335858 @default.
• W4205583718 cites W2104347254 @default.
• W4205583718 cites W2156353875 @default.
• W4205583718 cites W2288659104 @default.
• W4205583718 cites W2299181842 @default.
• W4205583718 cites W2339631364 @default.
• W4205583718 cites W2435563082 @default.
• W4205583718 cites W2513174800 @default.
• W4205583718 cites W2516963312 @default.
• W4205583718 cites W2525223387 @default.
• W4205583718 cites W2527905628 @default.
• W4205583718 cites W2560367415 @default.
• W4205583718 cites W2572174216 @default.
• W4205583718 cites W2592144107 @default.
• W4205583718 cites W2602081304 @default.
• W4205583718 cites W2635951006 @default.
• W4205583718 cites W2748446166 @default.
• W4205583718 cites W2763355946 @default.
• W4205583718 cites W2767268588 @default.
• W4205583718 cites W2774712455 @default.
• W4205583718 cites W2783897381 @default.
• W4205583718 cites W2784371446 @default.
• W4205583718 cites W2791483720 @default.
• W4205583718 cites W2793724302 @default.
• W4205583718 cites W2794342655 @default.
• W4205583718 cites W2796582438 @default.
• W4205583718 cites W2885326465 @default.
• W4205583718 cites W2887577080 @default.
• W4205583718 cites W2892640821 @default.
• W4205583718 cites W2895608724 @default.
• W4205583718 cites W2907814135 @default.
• W4205583718 cites W2910245285 @default.
• W4205583718 cites W2922024836 @default.
• W4205583718 cites W2925446385 @default.
• W4205583718 cites W2959497269 @default.
• W4205583718 cites W2974585575 @default.
• W4205583718 cites W2976744492 @default.
• W4205583718 cites W2984473065 @default.
• W4205583718 cites W2988049398 @default.
• W4205583718 cites W2990418039 @default.
• W4205583718 cites W2992690696 @default.
• W4205583718 cites W2996629418 @default.
• W4205583718 cites W3004475955 @default.
• W4205583718 cites W3009099064 @default.
• W4205583718 cites W3037506839 @default.
• W4205583718 cites W3038227983 @default.
• W4205583718 cites W3047751348 @default.
• W4205583718 cites W3049075450 @default.
• W4205583718 cites W3093156106 @default.
• W4205583718 cites W3094093870 @default.
• W4205583718 cites W3135105663 @default.
• W4205583718 cites W3149764185 @default.
• W4205583718 cites W3155032836 @default.
• W4205583718 cites W3183331045 @default.
• W4205583718 doi "https://doi.org/10.1177/17588359211068732" @default.
• W4205583718 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35035536" @default.
• W4205583718 hasPublicationYear "2022" @default.
• W4205583718 type Work @default.
• W4205583718 citedByCount "5" @default.
• W4205583718 countsByYear W42055837182022 @default.
• W4205583718 countsByYear W42055837182023 @default.
• W4205583718 crossrefType "journal-article" @default.
• W4205583718 hasAuthorship W4205583718A5000828978 @default.
• W4205583718 hasAuthorship W4205583718A5011980528 @default.
• W4205583718 hasAuthorship W4205583718A5017519850 @default.
• W4205583718 hasAuthorship W4205583718A5020903295 @default.
• W4205583718 hasAuthorship W4205583718A5031320827 @default.
• W4205583718 hasAuthorship W4205583718A5036720036 @default.
• W4205583718 hasAuthorship W4205583718A5048833234 @default.
• W4205583718 hasAuthorship W4205583718A5049113012 @default.
• W4205583718 hasAuthorship W4205583718A5057474625 @default.
• W4205583718 hasAuthorship W4205583718A5064697305 @default.
• W4205583718 hasAuthorship W4205583718A5071926090 @default.
• W4205583718 hasAuthorship W4205583718A5084782886 @default.

• next